Succinate is elevated in many pathological situations with a metabolic and/or a inflammatory component. Building on the breakthrough science from DIAMET research team, we are currently developing drugs able to reduce succinate to improve metabolism and reduce inflammation.

We have a diversified pipeline of biological proprietary succinate-modulating compounds with different Target Product Profiles.

Our first asset is a first-in-class, gut- restricted, monitorable, succinate-modulating therapy able to decrease intestinal and systemic succinate, improve inflammmation and metabolism and prevent fibrosis that has Inflamamtory bowel Disease as a Primary Indication.